









Markets
/
Stocks
/
nasdaq-dtil
/

Precision BioSciences Inc

DTIL

5.480USD

-1.060-16.20%

Market hours （ET）Quotes delayed by 15 min

8.96MMarket Cap

LossP/E TTM



Precision BioSciences Inc

5.480

-1.060-16.20%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Precision BioSciences Inc

Currency: USD Updated: 2026-03-27

Key Insights

Precision BioSciences Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 105 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 32.00.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Precision BioSciences Inc's Score

Industry at a Glance

Industry Ranking

105 / 391

Overall Ranking

220 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Precision BioSciences Inc Highlights

StrengthsRisks

Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.

Growing

The company is in a growing phase, with the latest annual income totaling USD 34.26M.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Undervalued

The company’s latest PE is -1.69, at a low 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 326.48K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.91.

Analyst Rating

Based on 4 analysts

Strong Buy

Current Rating

32.000

Target Price

+389.30%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Precision BioSciences Inc is 5.67, ranking 336 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 34.20M, representing a year-over-year increase of 5261.13%, while its net profit experienced a year-over-year increase of 213.46%.

Score

Industry at a Glance

Previous score

5.67

Change



Financials

5.99

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.24

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.18

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Precision BioSciences Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Precision BioSciences Inc is 8.57, ranking 36 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.69, which is -434.79% below the recent high of 5.65 and -19.00% above the recent low of -2.01.

Score

Industry at a Glance

Previous score

8.57

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 105/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Precision BioSciences Inc is 9.00, ranking 19 out of 391 in the Biotechnology & Medical Research industry. The average price target is 25.50, with a high of 60.00 and a low of 19.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Strong Buy

Current Rating

32.000

Target Price

+389.30%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Precision BioSciences Inc

DTIL

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Precision BioSciences Inc is 7.22, ranking 65 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 7.74 and the support level at 4.16, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.76

Change

-1.54

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.023

Neutral

RSI(14)

57.816

Neutral

STOCH(KDJ)(9,3,3)

32.584

Sell

ATR(14)

0.643

Low Volatility

CCI(14)

-11.789

Neutral

Williams %R

52.685

Neutral

TRIX(12,20)

2.133

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

6.390

Sell

MA10

6.545

Sell

MA20

5.725

Sell

MA50

4.670

Buy

MA100

4.821

Buy

MA200

5.004

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Precision BioSciences Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 36.99%, representing a quarter-over-quarter decrease of 47.59%. The largest institutional shareholder is The Vanguard, holding a total of 906.78K shares, representing 3.67% of shares outstanding, with 37.63% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Bleichroeder LP

1.07M

Boothbay Fund Management, LLC

178.53K

-10.73%

Lynx1 Capital Advisors LLC

1.04M

+0.63%

The Vanguard Group, Inc.

Star Investors

492.60K

+21.52%

Readout Capital LP

686.44K

-25.39%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Precision BioSciences Inc is 2.44, ranking 223 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.01. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.